Quick Answer
aTYR PHARMA INC reported Revenue From Contract With Customer Excluding Assessed Tax of $190.0 thousand for the year ending 2025.
- aTYR PHARMA INC showed a decrease of -19.1% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from aTYR PHARMA INC's annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2019: $94.0 thousand | Q3 2019: $184.0 thousand | Q1 2020: $8.07 million | Q2 2020: $189.0 thousand | Q3 2020: $148.0 thousand | Q3 2022: $0.00 | Q1 2023: $0.00 | Q2 2023: $0.00 | Q3 2023: $353.0 thousand | Q1 2024: $235.0 thousand | Q2 2024: $0.00 | Q3 2024: $0.00 | Q1 2025: $0.00 | Q2 2025: $0.00 | Q3 2025: $190.0 thousand.
- Over the full 7 years of available data (2019 to 2025), aTYR PHARMA INC's Revenue From Contract With Customer Excluding Assessed Tax has declined by 55.0%.
- Historical annual values: Fiscal year 2025: $190.0 thousand | Fiscal year 2024: $235.0 thousand | Fiscal year 2023: $353.0 thousand | Fiscal year 2022: $10.39 million | Fiscal year 2021: $0.00 | Fiscal year 2020: $10.46 million | Fiscal year 2019: $422.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: